In addition, given the role of TNF in mediating tumor growth [5], the risk of malignancy with anti-TNF therapy has been a concern [7], and there is substantial evidence that the chronic inflammation inherent in the conditions treated with anti-TNF therapy is itself associated with an increased potential for malignancy [6, 8]. This evidence concerns the gene TNF and neoplasm.